Literature DB >> 33176137

Functional Pro-metastatic Heterogeneity Revealed by Spiked-scRNAseq Is Shaped by Cancer Cell Interactions and Restricted by VSIG1.

Carolina Bernal1, Marianna Silvano1, Yann Tapponnier1, Santosh Anand1, Cecilia Angulo1, Ariel Ruiz i Altaba2.   

Abstract

How cells with metastatic potential, or pro-metastatic states, arise within heterogeneous primary tumors remains unclear. Here, we have used one index primary colon cancer to develop spiked-scRNAseq to link omics-defined single-cell clusters with cell behavior. Using spiked-scRNAseq we uncover cell populations with differential metastatic potential in which pro-metastatic states are correlated with the expression of signaling and vesicle-trafficking genes. Analyzing such heterogeneity, we define an anti-metastatic, non-cell-autonomous interaction originating from non-/low-metastatic cells, and identify membrane VSIG1 as a critical mediator of this interaction. VSIG1 acts to restrict the development of pro-metastatic states autonomously and non-cell autonomously, in part by inhibiting YAP/TAZ-TEAD signaling. As VSIG1 re-expression is able to reduce metastatic behavior from multiple colon cancer cell types, the regulation of VSIG1 or its effectors opens new interventional opportunities. In general, we propose that crosstalk between cancer cells, including the action of VSIG1, dynamically defines the degree of pro-metastatic intra-tumoral heterogeneity.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  VSIG1; cell interactions; clusters; metastasis; metastatic repressor; non-cell-autonomous; phenotype/expressed genotype; pro-metastatic states; scRNAseq; single cell

Year:  2020        PMID: 33176137     DOI: 10.1016/j.celrep.2020.108372

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  3 in total

1.  Estrogen Receptor-Regulated Gene Signatures in Invasive Breast Cancer Cells and Aggressive Breast Tumors.

Authors:  Emily Smart; Svetlana E Semina; Luis H Alejo; Nidhi S Kansara; Jonna Frasor
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

Review 2.  V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy.

Authors:  Xia Zhou; Sohail Khan; Dabing Huang; Lu Li
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

3.  Interaction between cadherins, vimentin, and V-set and immunoglobulin domain containing 1 in gastric-type hepatocellular carcinoma.

Authors:  Simona Gurzu; Janos Szederjesi; Haruhiko Sugimura; Rita Szodorai; Cornelia Braicu; Laszlo Kobori; Decebal Fodor; Ioan Jung
Journal:  Histochem Cell Biol       Date:  2021-06-25       Impact factor: 4.304

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.